• Evommune CFO Kyle Carver cut his stake to 59,335 shares in transactions dated May 28, 2026.
• Sold 18,175 shares at a weighted average price of $22.84.
• Acquired 15,000 shares at $2.99 through an employee stock option exercise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001757072-26-000005), on June 01, 2026, and is solely responsible for the information contained therein.